低剂量全身皮肤电子束治疗作为Sézary综合征多模式方案的一部分:临床、免疫与分子分析
该回顾性病例系列纳入3例对多模式系统治疗难治的IVA1期CD4+ Sézary综合征患者,在光分离置换、贝沙罗汀和干扰素-γ基础上加用低剂量全身皮肤电子束治疗(TSEBT)。缓解持续24至30个月,2例完全缓解持续中;TSEBT后免疫耗竭标志物显著降低,干扰素-γ产生能力增强,高通量测序显示2/3患者循环克隆接近完全清除。
要点
- 低剂量TSEBT联合光分离置换、贝沙罗汀和干扰素-γ可使难治性SS获得24至30个月缓解。
- TSEBT后PD-1、TIGIT、CTLA4、TOX和Foxp3等免疫耗竭标志物较基线显著降低。
- 3例中2例循环克隆接近完全清除,提示该多模式方案值得开展临床试验。
核心结论
- 低剂量TSEBT作为多模式方案的一部分,可使部分Sézary综合征患者获得长期临床和分子缓解。
- 由于SS长期缓解少见,该方案显示出应用前景,应考虑开展临床试验。
研究设计与样本
- 回顾性病例系列,并额外检测患者捐赠样本以评估治疗反应。
- 患者在接受低剂量TSEBT前,均对多模式系统治疗难治。
主要发现
- 接受低剂量TSEBT并维持其他治疗后,缓解持续24至30个月,2例完全缓解持续中。
- TSEBT后PD-1、TIGIT、CTLA4、TOX和Foxp3等免疫耗竭标志物较基线显著降低。
- 激活刺激后淋巴细胞产生干扰素-γ的能力增强。
- 高通量测序显示3例中2例循环克隆接近完全清除,1例克隆水平稳定。
关键数值与推荐
- 皮肤病变范围采用改良严重度加权评估工具(modified severity weighted assessment tool)测量。
- 血液病变采用流式细胞术评估Sézary细胞计数、CD4:CD8比值,并对T细胞受体进行高通量测序。
- 免疫耗竭标志物检测包括循环CD4和CD8 T细胞上的PD-1、TIGIT、CTLA4、TOX和Foxp3。
- 干扰素-γ产生能力在激活刺激后测定。
临床怎么用
- 对多模式系统治疗难治的Sézary综合征患者,可考虑在光分离置换、贝沙罗汀和干扰素-γ基础上加用低剂量TSEBT。
- 治疗反应评估应结合皮肤评分、血液Sézary细胞计数与CD4:CD8比值、T细胞受体高通量测序及免疫耗竭标志物。
- 该方案目前仅为3例病例系列证据,临床应用应个体化并考虑临床试验背景。
局限性
- 样本量仅3例,属回顾性病例系列,证据级别有限。
- 研究未设对照组,无法明确低剂量TSEBT相对于其他治疗的独立贡献。
- 原文未报告长期随访 beyond 缓解持续时间及更多安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Sézary syndrome (SS) is an advanced form of cutaneous T-cell lymphoma with few long-term remissions observed. OBJECTIVE: To profile 3 patients with SS who have experienced long-term remission following the addition of low-dose total skin electron beam therapy (TSEBT) to systemic regimens of extracorporeal photopheresis, bexarotene, and interferon-γ. DESIGN, SETTING, AND PARTICIPANTS: This is a retrospective case series with additional investigations of patient-donated samples to assess therapeutic response. The study was conducted at the University of Pennsylvania Cutaneous Lymphoma Clinic and follows 3 patients with stage IVA1 CD4+ SS who presented to the clinic between November 1, 2009, and November 1, 2017, and who had a history of SS that was refractory to multimodality systemic therapy prior to receiving low-dose TSEBT. INTERVENTIONS: Patients were treated in a multimodality fashion with combined extracorporeal photopheresis, bexarotene, interferon-γ, and low-dose TSEBT. MAIN OUTCOMES AND MEASURES: To characterize treatment responses in these patients, the extent of skin disease was measured with the modified severity weighted assessment tool. Blood disease was measured with flow cytometric assessments of Sézary cell count, CD4:CD8 ratio, and high throughput sequencing of the T-cell receptors. To assess for restoration of immune function, we measured markers of immune exhaustion, including PD-1 (programmed cell death 1), TIGIT (T-cell immunoreceptor with immunoglobulin and ITIM domains), CTLA4 (cytotoxic T-lymphocyte-associated protein 4), TOX (thymocyte selection-associated high mobility group box protein), and Foxp3 (forkhead box P3) on circulating CD4 and CD8 T cells, along with production capacity of interferon-γ by lymphocytes following activation stimuli. RESULTS: Following administration of low-dose TSEBT and maintenance of the other therapies, remissions ranged from 24 to 30 months, with complete responses in 2 patients ongoing. Markers of immune exhaustion including PD-1, TIGIT, CTLA4, TOX, and Foxp3 were significantly reduced from baseline following TSEBT, along with enhanced production capacity of interferon-γ by lymphocytes following activation stimuli. High throughput sequencing demonstrated near-complete eradication of the circulating clone among 2 of 3 patients with stable levels in 1. CONCLUSIONS AND RELEVANCE: We describe 3 patients who achieved long-term clinical and molecular remissions following low-dose TSEBT as part of a multimodality regimen for treatment of SS. As long-term remissions in SS are uncommon, this approach demonstrates promise, and clinical trials should be considered.
引用
- Durgin JS, Jariwala NN, Wysocka M, et al. Low-Dose Total Skin Electron Beam Therapy as Part of a Multimodality Regimen for Treatment of Sézary Syndrome: Clinical, Immunologic, and Molecular Analysis. JAMA Dermatol. 2021. PMID: 33112366. doi:10.1001/jamadermatol.2020.3958
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。